Leukemia:北京基因组所等发现不同表观修饰的相互作用加速 MLL 白血病进展

2018-02-12 佚名 北京基因组研究所

MLL 白血病(Mixed lineage leukemia, MLL)是一类携带 MLL 基因重排的恶性血液肿瘤,病人具有完全缓解率低、易复发、生存期短的特点。中国科学院北京基因组研究所王前飞研究组致力于白血病的发生机制、临床特征及治疗研究。近日,该研究组与美国辛辛那提儿童医院黄刚研究组合作,首次揭示了两种不同组蛋白表观修饰相互作用,调控基因表达并加速 MLL 白血病进展的全新机制。相关成果以



A.SETD2 野生型的 MLL 白血病中(MLLr)高水平 H3K79me2 修饰促进 H3K36me3 修饰升高;表达水平发生变化的主要是 MLL 靶基因被激活。

B.SETD2 突变后(SETD2 LOF)MLL 白血病中 H3K36me3 修饰降低,但 H3K79me2 修饰进一步升高;传统的 MLL 靶基因表达水平并无进一步改变,而新的抑癌基因被抑制,癌基因被激活。

MLL 白血病(Mixed lineage leukemia, MLL)是一类携带 MLL 基因重排的恶性血液肿瘤,病人具有完全缓解率低、易复发、生存期短的特点。中国科学院北京基因组研究所王前飞研究组致力于白血病的发生机制、临床特征及治疗研究。近日,该研究组与美国辛辛那提儿童医院黄刚研究组合作,首次揭示了两种不同组蛋白表观修饰相互作用,调控基因表达并加速 MLL 白血病进展的全新机制。相关成果以 SETD2-mediated crosstalk between H3K36me3 and H3K79me2 in MLL-rearranged leukemia 为题,在线发表在 Leukemia 上。

近年来,表观调控因子在多种癌症中相继检测到突变,越来越多的研究显示它们在肿瘤发生中具有重要功能。SETD2 基因编码修饰组蛋白 H3 第 36 位赖氨酸三甲基化(H3K36me3)的甲基转移酶。在人类肾癌、神经胶质瘤、乳腺癌以及急性白血病等多种癌症中均检测到 SETD2 基因功能缺失性突变,提示其具有重要的抑癌基因功能。MLL 白血病中,MLL 融合蛋白会招募组蛋白甲基转移酶 DOT1L,引起异常高水平 H3K79me2 修饰并激活 MLL 靶基因表达。但单一的 H3K79me2 的组蛋白修饰异常是否足以驱动疾病进展,及在 SETD2 突变的 MLL 白血病中两种组蛋白修饰(H3K79me2 和 H3K36me3)之间是否相互作用以影响疾病进展,在国际上仍未有认识。

研究团队通过组学测序数据整合分析并结合功能实验验证发现,在 SETD2 野生型的 MLL 白血病中不仅 H3K79me2 异常高水平修饰,H3K36me3 水平也显着升高,并且两种组蛋白修饰显着富集于同一个基因集;研究进一步发现,在 SETD2 功能缺失的 MLL 白血病中,全基因组水平 H3K36me3 修饰降低,而 H3K79me2 修饰水平进一步升高;动态的组蛋白修饰并没有进一步激活传统认识的 MLL 靶基因,而是调控了一组新的基因集。其中抑癌基因 ASXL1 等被抑制,癌基因 ERG 等被激活,进而促进 MLL 白血病进展。

该研究在肿瘤研究领域首次揭示了全基因组水平两个表观调控通路的功能协同,表明 MLL 白血病中致癌通路 DOT1L-H3K79me2 和抑癌通路 SETD2-H3K36me3 在基因调控过程中相互作用。在临床治疗方面,研究发现了传统 MLL 靶基因以外的肿瘤发生相关基因,为临床提供了新的治疗靶点,有望解决白血病病人由于 SETD2 突变导致的化疗耐药难题。

研究工作得到了国家自然科学基金、中科院战略性先导科技专项等的资助。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1909234, encodeId=caf0190923428, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sun Dec 09 03:02:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416557, encodeId=9e21141655ebf, content=<a href='/topic/show?id=54d29024251' target=_blank style='color:#2F92EE;'>#表观修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90242, encryptionId=54d29024251, topicName=表观修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab453208753, createdName=wujh_7312820, createdTime=Wed Feb 14 04:02:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471576, encodeId=35b914e157602, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Wed Feb 14 04:02:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569307, encodeId=0204156930e12, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Wed Feb 14 04:02:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287526, encodeId=235a28e52639, content=呵呵.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4c106013, createdName=Drhzm308, createdTime=Tue Feb 13 06:52:53 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287372, encodeId=bd6628e372f6, content=好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Feb 12 13:39:34 CST 2018, time=2018-02-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1909234, encodeId=caf0190923428, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sun Dec 09 03:02:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416557, encodeId=9e21141655ebf, content=<a href='/topic/show?id=54d29024251' target=_blank style='color:#2F92EE;'>#表观修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90242, encryptionId=54d29024251, topicName=表观修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab453208753, createdName=wujh_7312820, createdTime=Wed Feb 14 04:02:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471576, encodeId=35b914e157602, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Wed Feb 14 04:02:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569307, encodeId=0204156930e12, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Wed Feb 14 04:02:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287526, encodeId=235a28e52639, content=呵呵.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4c106013, createdName=Drhzm308, createdTime=Tue Feb 13 06:52:53 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287372, encodeId=bd6628e372f6, content=好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Feb 12 13:39:34 CST 2018, time=2018-02-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1909234, encodeId=caf0190923428, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sun Dec 09 03:02:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416557, encodeId=9e21141655ebf, content=<a href='/topic/show?id=54d29024251' target=_blank style='color:#2F92EE;'>#表观修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90242, encryptionId=54d29024251, topicName=表观修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab453208753, createdName=wujh_7312820, createdTime=Wed Feb 14 04:02:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471576, encodeId=35b914e157602, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Wed Feb 14 04:02:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569307, encodeId=0204156930e12, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Wed Feb 14 04:02:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287526, encodeId=235a28e52639, content=呵呵.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4c106013, createdName=Drhzm308, createdTime=Tue Feb 13 06:52:53 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287372, encodeId=bd6628e372f6, content=好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Feb 12 13:39:34 CST 2018, time=2018-02-12, status=1, ipAttribution=)]
    2018-02-14 ylz8405
  4. [GetPortalCommentsPageByObjectIdResponse(id=1909234, encodeId=caf0190923428, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sun Dec 09 03:02:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416557, encodeId=9e21141655ebf, content=<a href='/topic/show?id=54d29024251' target=_blank style='color:#2F92EE;'>#表观修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90242, encryptionId=54d29024251, topicName=表观修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab453208753, createdName=wujh_7312820, createdTime=Wed Feb 14 04:02:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471576, encodeId=35b914e157602, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Wed Feb 14 04:02:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569307, encodeId=0204156930e12, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Wed Feb 14 04:02:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287526, encodeId=235a28e52639, content=呵呵.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4c106013, createdName=Drhzm308, createdTime=Tue Feb 13 06:52:53 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287372, encodeId=bd6628e372f6, content=好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Feb 12 13:39:34 CST 2018, time=2018-02-12, status=1, ipAttribution=)]
    2018-02-14 zhangyxzsh
  5. [GetPortalCommentsPageByObjectIdResponse(id=1909234, encodeId=caf0190923428, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sun Dec 09 03:02:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416557, encodeId=9e21141655ebf, content=<a href='/topic/show?id=54d29024251' target=_blank style='color:#2F92EE;'>#表观修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90242, encryptionId=54d29024251, topicName=表观修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab453208753, createdName=wujh_7312820, createdTime=Wed Feb 14 04:02:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471576, encodeId=35b914e157602, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Wed Feb 14 04:02:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569307, encodeId=0204156930e12, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Wed Feb 14 04:02:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287526, encodeId=235a28e52639, content=呵呵.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4c106013, createdName=Drhzm308, createdTime=Tue Feb 13 06:52:53 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287372, encodeId=bd6628e372f6, content=好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Feb 12 13:39:34 CST 2018, time=2018-02-12, status=1, ipAttribution=)]
    2018-02-13 Drhzm308

    呵呵.学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1909234, encodeId=caf0190923428, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sun Dec 09 03:02:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416557, encodeId=9e21141655ebf, content=<a href='/topic/show?id=54d29024251' target=_blank style='color:#2F92EE;'>#表观修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90242, encryptionId=54d29024251, topicName=表观修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab453208753, createdName=wujh_7312820, createdTime=Wed Feb 14 04:02:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471576, encodeId=35b914e157602, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Wed Feb 14 04:02:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569307, encodeId=0204156930e12, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Wed Feb 14 04:02:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287526, encodeId=235a28e52639, content=呵呵.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4c106013, createdName=Drhzm308, createdTime=Tue Feb 13 06:52:53 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287372, encodeId=bd6628e372f6, content=好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Feb 12 13:39:34 CST 2018, time=2018-02-12, status=1, ipAttribution=)]
    2018-02-12 医者仁心5538

    好消息

    0

相关资讯

Blood:阿扎胞苷联合化疗药物治疗白血病患儿的效果和安全性评估。

越来越多的证据表明DNA过度异常甲基化与白血病发生、化疗耐药和复发相关。DNA甲基转移酶抑制剂,如阿扎胞苷和地西他滨,已经证实在体外可逆转耐药性和原发性白血病细胞对细胞毒性药物的敏感性。现有研究人员进行I期临床试验首次对阿扎胞苷联合化疗药物用于复发性/难治性白血病患儿的效果和安全性进行评估。招募了14位患者(12位急性髓性白血病[AML]患者,2位急性淋巴细胞白血病[ALL]患者)。所有患者接受阿

JCO:TP53胚系突变与儿童急性淋巴细胞白血病的易感性和预后的关系

急性淋巴细胞白血病(ALL)是儿童常见的恶性肿瘤,越来越多的证据显示其与遗传易感性相关。TP53是重要的抑癌基因,在多种肿瘤中检测到TP53的突变。近日,《JCO》发表的一项研究在大样本量的儿童ALL患者检测TP53的胚系突变,并探索致病性突变与患者治疗疗效和预后的关系。

FDA批准砒霜联合维甲酸一线治疗白血病

1月15日,Teva宣布FDA批准Trisenox(arsenic rioxide,三氧化二砷)注射液联合维甲酸(retinoic acid,RA)一线治疗存在t(15,17)易位或PML/RARα基因表达的新确诊的低风险成人急性早幼粒细胞白血病(APL)患者。在此之前,FDA基于已经公布在科学文献中的临床数据以及Teva对三氧化二砷全球安全数据库的回顾数据,授予了Trisenox优先审评资格。T

NEJM:CAR-T治疗ALL白血病患者的12个月总生存率达76%

对于高风险形式的急性淋巴细胞白血病(ALL)患者来说,诺华的CAR-T细胞产品tisagenlecleucel(CTL019)绝对称得上是具有里程碑意义的个性化治疗方法。今日,《新英格兰医学杂志》上公开发表了一项其最新的全球试验结果,表明该CAR-T疗法在儿童和年轻成人B细胞淋巴细胞白血病患者中持续显示出高耐用性以及完全缓解状态,并且治疗过程中发生的大多数副作用都是短暂且可逆的(CHOP(费城儿童

Cell Stem Cell:科学家发现调控造血干/祖细胞和白血病干/起始细胞自我更新及分化的重要信号轴!

本研究揭示了SPI1-METTL14-MYB/MYC信号轴在髓系分化以及白血病发生过程中的作用。

献血16年致身患白血病?专家:献血与患病之间没有关系

近日,一段“坚持无偿献血16年的她患了急性白血病”的视频在网上流传,视频关注了54岁来自湖南怀化的杨宏傅女士,从2001年起坚持无偿献血16年,如今却身患急性髓系白血病的现状。